Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Smallpox

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Smallpox. Displaying page 1 of 1.
    EudraCT Number: 2012-005137-37 Sponsor Protocol Number: POX-MVA-035 Start Date*: 2013-07-15
    Sponsor Name:Bavarian Nordic A/S
    Full Title: Open-label, non-controlled, multicenter immunogenicity and safety study of MVA-BN® smallpox vaccine in children from birth to less than 12 years of age
    Medical condition: Prevention of smallpox infection in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10041197 Smallpox PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001781-14 Sponsor Protocol Number: POX-MVA-005 Start Date*: 2006-04-11
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A partially randomized, partially double-blind, placebo-controlled Phase II non-inferiority study to evaluate immunogenicity and safety of one and two doses of MVA-BN (IMVAMUNE™) smallpox vaccine i...
    Medical condition: Healthy subjects - prevention of smallpox infection
    Disease: Version SOC Term Classification Code Term Level
    8.0 10041197 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006297-28 Sponsor Protocol Number: POX-MVA-023 Start Date*: 2008-07-30
    Sponsor Name:Bavarian Nordic A/S
    Full Title: An open-label Phase II study to evaluate immunogenicity and safety of a single IMVAMUNE® booster vaccination two years after the last IMVAMUNE® vaccination in former POX-MVA-005 vaccinees
    Medical condition: Healthy subjects - prevention of smallpox infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041197 Smallpox PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018334-51 Sponsor Protocol Number: POX-MVA-032 Start Date*: 2010-07-15
    Sponsor Name:Bavarian Nordic A/S
    Full Title: An open-label, non-controlled study to immunize healthy volunteers actively working with or in the vicinity of replicating Vaccinia virus with IMVAMUNE® (MVA-BN®)
    Medical condition: Healthy subjects actively working with or in the vicinity of replicating Vaccinia virus will receive immunization IMVAMUNE to offer protection against accidential Vaccinia virus infection.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10041197 Smallpox PT
    12.1 10066048 Vaccinia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000715-19 Sponsor Protocol Number: VVL05 Start Date*: 2006-04-10
    Sponsor Name:Sanofi Pasteur SA
    Full Title: A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated with One Dose of Smallpox Vaccine (LISTER Strain).
    Medical condition: Five year follow-up of healthy adults already vaccinated in a previous trial
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002175-32 Sponsor Protocol Number: VVL04 Start Date*: 2005-07-22
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Take evaluation and safety of smallpox vaccine (LISTER strain) in naïve healthy adults
    Medical condition: Vaccination of vaccinia-naive healthy adults (18-25 years old)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012591-27 Sponsor Protocol Number: VAC037 Start Date*: 2009-11-16
    Sponsor Name:University of Oxford
    Full Title: A phase I/IIa study to assess the safety and immunogenicity of new malaria vaccine candidates AdCh63 MSP1 alone and with MVA MSP1
    Medical condition: Plasmodium Falciparum Malaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005477-24 Sponsor Protocol Number: VAC045 Start Date*: 2012-02-28
    Sponsor Name:University of Oxford
    Full Title: A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-boost Malaria Vaccine Candidates: ChAd63 and MVA encoding ME-TRAP and the same Viral Vectors encoding CS
    Medical condition: Plasmodium falciparum infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018341-56 Sponsor Protocol Number: VAC039 Start Date*: 2010-05-07
    Sponsor Name:University of Oxford
    Full Title: A phase I/IIa sporozoite challenge study to assess the safety, immunogenicity and protective efficacy of new malaria vaccine candidates; AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP...
    Medical condition: Malaria (plasmodium falciparum)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021196-85 Sponsor Protocol Number: BNIT-PRV-301 Start Date*: 2012-05-04
    Sponsor Name:Bavarian Nordic, Inc.
    Full Title: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
    Medical condition: Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) EE (Prematurely Ended) IS (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:50:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA